Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815731 | 0.89 | CYP2C9 (0.45) | CYP2C9SMN1; SMN2L3MBTL1KMT2ANPC1 | |
| SCHEMBL12017707 | 0.87 | L3MBTL1 (0.46) | CYP2C9SMN1; SMN2L3MBTL1KMT2ANPC1 | |
| SCHEMBL11959661 | 0.85 | L3MBTL1 (0.49) | CYP2C9SMN1; SMN2L3MBTL1KMT2ANPC1 | |
| SCHEMBL20207653 | 0.84 | MRGPRX4 (0.43) | CYP2C9MRGPRX4HTR1A | |
| SCHEMBL19489148 | 0.84 | SSTR4 (0.50) | L3MBTL1MAPTMRGPRX4LMNAKDM4E | |
| SCHEMBL17815713 | 0.82 | MAPT (0.49) | CYP2C9SMN1; SMN2L3MBTL1KMT2ANPC1 | |
| SCHEMBL17815717 | 0.82 | SYK (0.47) | CYP2C9 | |
| SCHEMBL12526094 | 0.81 | VDR (0.54) | CYP2C9SMN1; SMN2L3MBTL1KMT2ANPC1 | |
| SCHEMBL17815773 | 0.81 | SMN1; SMN2 (0.41) | CYP2C9SMN1; SMN2L3MBTL1KMT2ANPC1 | |
| SCHEMBL20206858 | 0.80 | CYP2C9 (0.44) | CYP2C9SMN1; SMN2L3MBTL1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | CYP2C9 3288/4885SMN1; SMN2 714/4885L3MBTL1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.